The CEO expects about six trials to read out over the next 12 months. The idiopathic hypersomnia study reads out at the end of the year, and three phase three programs for NT1 and NT2 read out in the middle of the summer. An ADHD phase 2 dose-ranging study follows in the early fall.
ALKS · Alkermes plc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Alkermes plc settled Teva’s LYBALVI patent litigation, granting Teva a non-exclusive, royalty-free U.S. license beginning November 12, 2039, or May 12, 2040 if pediatric exclusivity is obtained. The parties filed a Stipulation of Dismissal with Prejudice on November 9, 2026.
Alkermes reported proprietary product net sales of $417.3 million, up 31% year-over-year, and expects six orexin studies to read out over the next year.
Alkermes reported net income of $16.3 million for the three months ended September 30, 2026, but a $49.7 million nine-month net loss as Avadel-related costs rose. LUMRYZ contributed $89.9 million in quarterly product sales, lifting net product sales to $417.3 million.
Alkermes plc reported third-quarter revenues of $480.1 million and GAAP net income of $16.3 million for 2026, including LUMRYZ revenue of $89.9 million, and reiterated its 2026 financial expectations.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 28, 2026TL;DR. Proprietary net sales rose 34% to $411.7 million, with Lybalvi prescriptions up 18%. Full-year GAAP net loss guidance widened to $95 to $115 million from $70 to $90 million, and Lybalvi gross-to-net adjustments are now expected in the high 30s.
- + Proprietary net sales rose 34% year-over-year to $411.7 million.
- + Lybalvi revenue grew 12% and prescriptions grew 18% year-over-year.
- + Lybalvi is now covered for more than 80% of insured lives after Part D plan expansion.
- + No authorized generic of Vivitrol is expected in 2027.
- + Lumerize IH supplemental NDA submission is planned by year-end.
- + Orexin agonist long-term extension data show sustained wakefulness gains in NT1 and NT2.
- − Full-year GAAP net loss guidance widened to $95 to $115 million from $70 to $90 million.
- − Lybalvi gross-to-net adjustments are now expected in the high 30s, with growth to net expanding in the second half.
- − GAAP net income fell to $0.5 million from $87.1 million, and six-month GAAP net was a $(66.0) million loss versus $109.6 million income a year earlier.
- − SG&A rose to $217.6 million from $170.8 million year-over-year.
- − Timing of Vivitrol generic market entry in 2027 remains uncertain.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ARISTADA and ARISTADA INITIO product sales, net | $103.9M | FY2026 Q3 | +6.0% |
|
|
|||
| LUMRYZ product sales, net | $89.92M | FY2026 Q3 | — |
|
|
|||
| VIVITROL product sales, net | $127.56M | FY2026 Q3 | +5.3% |
|
|
|||
| Alixorexton external R&D expenses | $28.8M | Three Months Ended June 30, 2026 filing | +21.0% |
|
|
|||
| Long-acting INVEGA products manufacturing and royalty revenues | $27.4M | Three Months Ended June 30, 2026 filing | — |
| LUMRYZ external R&D expenses | $4.7M | Three Months Ended June 30, 2026 filing | — |
|
|
|||
| LYBALVI product sales, net | $93.9M | Three Months Ended June 30, 2026 filing | — |
| Other manufacturing and royalty revenues | $26.3M | Three Months Ended June 30, 2026 filing | — |
| VUMERITY manufacturing and royalty revenues | $30.6M | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALKS
this stock
Alkermes plc.
|
$7.87B | +67.4% | -5.2% | — | 11.7% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 31
The CEO expects about six trials to read out over the next 12 months. The idiopathic hypersomnia study reads out at the end of the year, and three phase three programs for NT1 and NT2 read out in the middle of the summer. An ADHD phase 2 dose-ranging study follows in the early fall.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALKS | -2.2% | +7.8% | +11.1% | +3.3% | +67.4% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.7% | +13.3% | +14.5% | +6.7% | +60.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.